Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Good links!
"not being privy to all of the same information they are dealing with I won't hazard a guess at which route would be better using Brilacidin."
I know you don't have all the information they do, but you did say that "A reformaltion into a gel or foam enema will be quicker and the trial should be faster."
And I pointed out that a trial using the liquid enema purportedly resulted in Clinical Remission, as defined, at Day 42 in 10 out of the 15 patients who finished the trial. If true, that seems extraordinary and I'm not sure what other facts one would need to know.

Out of curiosity I asked my gastroenterologist just the other day about one of the TV promoted UC drugs (I think it was Entyvio). After a variety of treatments, two of which I still use, Remicade put my UC in remission about 3 years ago. His response was that the promoted drug has some nasty side effects (Remicade does, too) but more importantly that it was common practice in the field to not make a change as long as the current therapy was working. (I call it "You don't get off a winning horse" and it doesn't just apply to gastroenterology.)

But that would seem to be exactly what IPIX is doing and one should wonder why. Ideally the Company would test the best product possible but unless I'm mistaken (always possible) there are no other enemas claiming a remission rate of 67% in the targeted indications (basically UP). Unless there's a fear that those results can't be repeated it's hard to see, given the Company's financial condition and the status of its pipeline, why it wouldn't go forward with its existing product today instead of adding the development time and perhaps some risk to test a product with different physical properties.

Why get off a winning horse? I wouldn't think that this Company would have that luxury.


ps. Since one of your links addressed the use of a delayed release pill for UC (one of my treatments is a Mesalamine delayed release tablet....there are several on the market) I thought I'd note the section. It's worth reading:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215502/
b. Delayed (Time Controlled Release System) Release Drug Delivery to Colon

If I'm not mistaken (again) there are non-biologic pills on the market now, so I'm not sure what would make a B pill disruptive to the market:
"The end goal is to disrupt the market by creating a world-class, affordable small molecule in tablet form as a new treatment option with clear advantages over today’s commonly used biologics for patients with extensive IBD, such as Ulcerative Colitis (UC)."